{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T20:31:41Z","timestamp":1747168301491,"version":"3.40.5"},"reference-count":17,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revue Neurologique"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.neurol.2024.06.003","type":"journal-article","created":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T11:23:25Z","timestamp":1720092205000},"page":"711-714","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Advocating for rituximab as first-line treatment for NMOSD-AQP4 patients in France: Cost and efficacy considerations"],"prefix":"10.1016","volume":"180","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6291-8771","authenticated-orcid":false,"given":"Romain","family":"Deschamps","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Papeix","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3834-2981","authenticated-orcid":false,"given":"Xavier","family":"Ayrignac","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2459-2480","authenticated-orcid":false,"given":"Bertrand","family":"Bourre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3386-6308","authenticated-orcid":false,"given":"Jonathan","family":"Ciron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3985-1297","authenticated-orcid":false,"given":"Mikael","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3683-5582","authenticated-orcid":false,"given":"Nicolas","family":"Collongues","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kumaran","family":"Deiva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7oise","family":"Durand Dubief","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David-Axel","family":"Laplaud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabeth","family":"Maillart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8119-7794","authenticated-orcid":false,"given":"Laure","family":"Michel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1986-7945","authenticated-orcid":false,"given":"Julie","family":"Pique","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aur\u00e9lie","family":"Ruet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Thouvenot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4029-2012","authenticated-orcid":false,"given":"H\u00e9l\u00e8ne","family":"Z\u00e9phir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Romain","family":"Marignier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bertrand","family":"Audoin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.neurol.2024.06.003_bib0090","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1001\/jamaneurol.2023.4514","article-title":"Potential medicare and medicaid savings on anti-CD20 therapy for multiple sclerosis","volume":"81","author":"Kim","year":"2024","journal-title":"JAMA Neurol"},{"issue":"4","key":"10.1016\/j.neurol.2024.06.003_bib0095","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S1474-4422(20)30066-1","article-title":"Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"19","author":"Tahara","year":"2020","journal-title":"Lancet Neurol"},{"issue":"36","key":"10.1016\/j.neurol.2024.06.003_bib0100","doi-asserted-by":"crossref","first-page":"e30347","DOI":"10.1097\/MD.0000000000030347","article-title":"A meta-analysis on efficacy and safety of rituximab for neuromyelitis optica spectrum disorders","volume":"101","author":"Dong","year":"2022","journal-title":"Medicine (Baltimore)"},{"issue":"10","key":"10.1016\/j.neurol.2024.06.003_bib0105","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1002\/acn3.51451","article-title":"A meta-analysis comparing first-line immunosuppressants in neuromyelitis optica","volume":"8","author":"Giovannelli","year":"2021","journal-title":"Ann Clin Transl Neurol"},{"issue":"9","key":"10.1016\/j.neurol.2024.06.003_bib0110","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1007\/s00415-017-8590-0","article-title":"Comparison of the efficacy of azathioprine and rituximab in neuromyelitis optica spectrum disorder: a randomized clinical trial","volume":"264","author":"Nikoo","year":"2017","journal-title":"J Neurol"},{"key":"10.1016\/j.neurol.2024.06.003_bib0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.neurol.2024.01.008","article-title":"Disease-modifying treatments for neuromyelitis optica spectrum disorder in the context of a new generation of biotherapies","author":"Demuth","year":"2024","journal-title":"Rev Neurol (Paris)"},{"issue":"10206","key":"10.1016\/j.neurol.2024.06.003_bib0120","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/S0140-6736(19)31817-3","article-title":"Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2\/3 trial","volume":"394","author":"Cree","year":"2019","journal-title":"Lancet"},{"issue":"22","key":"10.1016\/j.neurol.2024.06.003_bib0125","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1056\/NEJMoa1901747","article-title":"Trial of satralizumab in neuromyelitis optica spectrum disorder","volume":"381","author":"Yamamura","year":"2019","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.neurol.2024.06.003_bib0130","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1056\/NEJMoa1900866","article-title":"Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder","volume":"381","author":"Pittock","year":"2019","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.neurol.2024.06.003_bib0135","doi-asserted-by":"crossref","first-page":"e438","DOI":"10.1212\/WNL.0000000000207443","article-title":"Rituximab de-escalation in patients with neuromyelitis optica spectrum disorder","volume":"101","author":"Demuth","year":"2023","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.neurol.2024.06.003_bib0140","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.neurol.2017.11.005","article-title":"Recommendations for the use of Rituximab in neuromyelitis optica spectrum disorders","volume":"174","author":"Ciron","year":"2018","journal-title":"Rev Neurol (Paris)"},{"key":"10.1016\/j.neurol.2024.06.003_bib0145","doi-asserted-by":"crossref","first-page":"103352","DOI":"10.1016\/j.msard.2021.103352","article-title":"Inebilizumab for treatment of neuromyelitis optica spectrum disorder in patients with prior rituximab use from the N-MOmentum study","volume":"57","author":"Flanagan","year":"2022","journal-title":"Mult Scler Relat Disord"},{"issue":"10","key":"10.1016\/j.neurol.2024.06.003_bib0150","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1080\/14737167.2023.2267176","article-title":"Inebilizumab for neuromyelitis optica spectrum disorders in Italy: a budget impact model","volume":"23","author":"Lazzaro","year":"2023","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"11","key":"10.1016\/j.neurol.2024.06.003_bib0155","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1001\/archneurol.2011.154","article-title":"Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years","volume":"68","author":"Kim","year":"2011","journal-title":"Arch Neurol"},{"key":"10.1016\/j.neurol.2024.06.003_bib0160","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s00415-023-11910-z","article-title":"Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) \u2013 revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: attack therapy and long-term management","volume":"271","author":"K\u00fcmpfel","year":"2024","journal-title":"J Neurol"},{"key":"10.1016\/j.neurol.2024.06.003_bib0165","doi-asserted-by":"crossref","first-page":"87","DOI":"10.2147\/ITT.S287652","article-title":"Drug treatment of neuromyelitis optica spectrum disorders: out with the old, in with the new?","volume":"10","author":"Held","year":"2021","journal-title":"Immunotargets Ther"},{"issue":"4","key":"10.1016\/j.neurol.2024.06.003_bib0170","doi-asserted-by":"crossref","first-page":"e200124","DOI":"10.1212\/NXI.0000000000200124","article-title":"International Delphi consensus on the management of AQP4-IgG+ NMOSD: recommendations for eculizumab, inebilizumab, and satralizumab","volume":"10","author":"Paul","year":"2023","journal-title":"Neurol Neuroimmunol Neuroinflamm"}],"container-title":["Revue Neurologique"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378724005563?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378724005563?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T20:17:20Z","timestamp":1728591440000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0035378724005563"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":17,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S0035378724005563"],"URL":"https:\/\/doi.org\/10.1016\/j.neurol.2024.06.003","relation":{},"ISSN":["0035-3787"],"issn-type":[{"type":"print","value":"0035-3787"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advocating for rituximab as first-line treatment for NMOSD-AQP4 patients in France: Cost and efficacy considerations","name":"articletitle","label":"Article Title"},{"value":"Revue Neurologique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurol.2024.06.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}